Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBS-1000 single ascending dose in healthy volunteers
NCT05721287Phase 1Completed
- Start
- Jan 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute pain comparing SBS-1000 with Placebo (2 arms). Primary endpoint: Adverse Events at 4 days. Started Jan 2023; status: completed.
02
Drugs
SBS-1000
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT05721287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05721287.